Latest filing published 05 Mar 2026 for COLLEGIUM PHARMACEUTICAL, INC, €1.6M. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Scott Dreyer (senior executive) discloses dealings in Collegium Pharmaceutical, Inc to SEC (Form 4). The record holds 24 filings, for trades running from 12 July 2021 to 3 March 2026.
The open-market record consists of 12 sales worth €4.6M, with no purchase. Outside the open market, there are 8 share grants and 4 option exercises. So far in 2026, the count stands at no purchases and 1 sale.
The record was last updated on 5 March 2026 with an open-market sale (€1.6M) in Collegium Pharmaceutical, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
24 of 24 declarations